Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies...

Celý popis

Podrobná bibliografie

Vydáno v:	Blood Ročník 139; číslo 6; s. 835
Hlavní autoři:	Cavo, Michele, San-Miguel, Jesus, Usmani, Saad Z, Weisel, Katja, Dimopoulos, Meletios A, Avet-Loiseau, Hervé, Paiva, Bruno, Bahlis, Nizar J, Plesner, Torben, Hungria, Vania, Moreau, Philippe, Mateos, Maria-Victoria, Perrot, Aurore, Iida, Shinsuke, Facon, Thierry, Kumar, Shaji, van de Donk, Niels W C J, Sonneveld, Pieter, Spencer, Andrew, Krevvata, Maria, Heuck, Christoph, Wang, Jianping, Ukropec, Jon, Kobos, Rachel, Sun, Steven, Qi, Mia, Munshi, Nikhil
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.02.2022
Témata:	Aged Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Disease-Free Survival Humans Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - drug therapy Neoplasm, Residual - diagnosis Neoplasm, Residual - drug therapy Prognosis Progression-Free Survival Treatment Outcome
ISSN:	1528-0020, 1528-0020
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!